Literature DB >> 12783347

Eradication of dysplastic Barrett's oesophagus using photodynamic therapy: long-term follow-up.

R Ackroyd1, C J Kelty, N J Brown, T J Stephenson, C J Stoddard, M W R Reed.   

Abstract

BACKGROUND AND STUDY AIMS: Barrett's oesophagus is a major risk factor for oesophageal adenocarcinoma, a condition which is rapidly increasing in incidence. Photodynamic therapy (PDT) is a developing treatment in which tissue damage is caused by the action of light on a previously administered photosensitizing agent. We present the results of long-term follow-up of its efficacy in patients with dysplastic Barrett's oesophagus. PATIENTS AND METHODS: A total of 40 patients with low-grade dysplasia in Barrett's oesophagus were treated with oral 5-aminolaevulinic acid (ALA) at a dose of 30 mg/kg, followed by laser endoscopy 4 hours later. Patients were treated between December 1995 and December 1998, and all were followed up regularly with endoscopy and biopsies in our surveillance programme.
RESULTS: Among the patients, 35 (88%) showed a macroscopic reduction in the area of the columnar epithelium, and in all 40 patients dysplasia was found to be eradicated at 1 month. The effect has been maintained for a median follow-up of 53 months (range 18-68 months), although one patient developed a late carcinoma in an untreated area of Barrett's oesophagus 3 years after the intervention.
CONCLUSIONS: Safe and effective ablation of low-grade dysplastic Barrett's oesophagus can be achieved with the use of ALA-induced PDT, and the effects are maintained in the long term.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12783347     DOI: 10.1055/s-2003-39676

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  14 in total

1.  What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.

Authors:  N J Shaheen; J M Inadomi; B F Overholt; P Sharma
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

2.  Endoscopic resection techniques and ablative therapies for Barrett's neoplasia.

Authors:  Jacobo Ortiz-Fernández-Sordo; Adolfo Parra-Blanco; Alejandro García-Varona; María Rodríguez-Peláez; Erika Madrigal-Hoyos; Irving Waxman; Luis Rodrigo
Journal:  World J Gastrointest Endosc       Date:  2011-09-16

3.  Locoregional therapies of liver metastases in a rat CC531 coloncarcinoma model results in increased resistance to tumour rechallenge.

Authors:  F H van Duijnhoven; R A E M Tollenaar; O T Terpstra; P J K Kuppen
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 4.  Barrett's oesophagus: the new endoscopic modalities have a future.

Authors:  J Deviere
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 5.  A systematic review and meta-analysis of the treatment for Barrett's esophagus.

Authors:  You-Ming Li; Lan Li; Chao-Hui Yu; You-Shi Liu; Cheng-Fu Xu
Journal:  Dig Dis Sci       Date:  2008-04-22       Impact factor: 3.199

Review 6.  American Gastroenterological Association technical review on the management of Barrett's esophagus.

Authors:  Stuart J Spechler; Prateek Sharma; Rhonda F Souza; John M Inadomi; Nicholas J Shaheen
Journal:  Gastroenterology       Date:  2011-03       Impact factor: 22.682

Review 7.  Operable gastro-oesophageal junctional adenocarcinoma: Where to next?

Authors:  Elizabeth C Smyth; David Cunningham
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

Review 8.  Low grade dysplasia in Barrett's esophagus: Should we worry?

Authors:  Vamshi P Jagadesham; Clive J Kelty
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

9.  Optimal conditions for successful ablation of high-grade dysplasia in Barrett's oesophagus using aminolaevulinic acid photodynamic therapy.

Authors:  Gary D Mackenzie; Jason M Dunn; C R Selvasekar; C Alexander Mosse; Sally M Thorpe; Marco R Novelli; Stephen G Bown; Laurence B Lovat
Journal:  Lasers Med Sci       Date:  2008-12-05       Impact factor: 3.161

10.  Phototoxic aptamers selectively enter and kill epithelial cancer cells.

Authors:  Cátia S M Ferreira; Melissa C Cheung; Sotiris Missailidis; Stuart Bisland; Jean Gariépy
Journal:  Nucleic Acids Res       Date:  2008-12-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.